Publications and Presentations
ACE-011 / Bone & Blood
Relevant Presentations:
ACE-011, a Soluble Activin Receptor Type IIA IgG-Fc Fusion Protein, Decreases Follicle Stimulating Hormone and Increases Bone-Specific Alkaline Phosphatase, a Marker of Bone Formation, in Postmenopausal Healthy Women (SABCS 2008)
RAP-011, a Soluble Activin Receptor Type IIA IgG-Fc-fusion Protein, is a Novel Anabolic Bone Agent that Prevents Bone Loss in a Mouse Model of Metastatic Breast Cancer (SABCS 2008)
ACE-011, a Soluble Activin Receptor Type IIA IgG-Fc Fusion Protein, Increases Hemoglobin and Hematocrit Levels in Postmenopausal Healthy Women (ASH 2008)
RAP-011 (a Soluble Activin Receptor Type IIa) Increases Bone Mineral Density in Combination with Prior Antiresorptive Therapy (ASBMR 2007)
A Soluble Activin Type II Receptor Prevents Myeloma Bone Disease (XIth International Myeloma Workshop 2007)
The Use of a Soluble Activin Receptor Type IIA as a Novel Anabolic Agent for Treatment of Bone Loss (ECCEO 2007)
Comparison of Skeletal Effects of a Soluble Activin Receptor Type IIA (ActRIIa), PTH and Zolendronate in Ovariectomized Mice (ECCEO 2007)
Relevant Manuscripts:
Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. AD Chantry, et al. JBMR, 2010
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Lotinun S, et al. Bone, 46:1082-8, 2010.
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. S Vallet, et al. PNAS, 107:5124-5129, 2010
Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). R Fajardo et al. Bone, 46:64-71
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women, J Ruckle, et al. Journal of Bone and Mineral Research, 24: 744-752, 2009
A Soluble Activin type IIA Receptor Induces Bone Formation and Improves Skeletal Integrity, R. Scott Pearsall, et al., PNAS, 105: 7087-7087, 2008
Mechanisms of Anabolic Therapies for Osteoporosis, E. Canalis, et al., The New England Journal of Medicine. 357:905-916, 2007
Inhibitory effects of activin-a on osteoblast differentiation during cultures of fetal rat calvarial cells, T. Ikenoue et. al., J. Cell. Biochem. 75:206-214, 1999
Activin A Is an Essential Cofactor for Osteoclast Induction, K. Fuller et. al., BBRC. 268:2–7, 2000
ACE-031 / Muscle
Relevant Presentations:
ACE-031, a Soluble Activin Receptor Type IIB IgG-Fc Fusion Protein, Increases Lean Body Mass (LBM) and Muscle Volume After a Single Dose in Postmenopausal Healthy Women (WMS 2009)
Treatment with a Soluble Activin Receptor IIb Attenuates Glucocorticoid-induced Muscle Loss (WMS 2007)
Treatment with a Soluble Activin Receptor IIb Causes Increased Muscle Mass and Strength in mdx Mice (Gordon Research Conference on Myogenesis 2007)
Relevant Manuscripts:
Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type. Cadena SM et al. J Appl Physiol, 2010
A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Koncarevic A et al. Endocrinology, 2010
Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. Sako D et al. J Biol Chem, 285:21037-48, 2010
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Pistilli E, et al. Am J Physiol Regul Integr Comp Physiol, 298:96-103, 2010
The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Akpan I, et al. Int J Obes, 33:1265-73, 2009
A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Morrison BM et al. Exp Neurol, 217:258-68, 2009
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Q. Li, et al. Mol. Hum. Reproduc. Aug 18, 2007
A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs, Mosher DS et al. PLoS Genet 3(5): e79, 2007
Regulation of myostatin activity and muscle growth, S-J Lee et. al., PNAS, 98:9306-9311, 2001
Regulation of muscle growth by multiple ligands signaling through activin type II receptors, S-J Lee et. al., PNAS 102:18117-18122, 2005
Muscular atrophy of caveolin-3–deficient mice is rescued by myostatin inhibition, Y. Ohsawa et. al., J. Clin. Invest. 116:2924–2934, 2006
ACE-041 / Vasculature
Relevant Presentations:
Inhibition of ALK1 Signaling Using RAP-041, a Novel Soluble ALK1-Fc Compound, Prevents Endothelial Cell Cord Formation In Vitro and Inhibits Angiogenesis In Vivo (AACR 2009)
RAP-041, a Soluble Activin Receptor-Like Kinase (ALK1) Fusion Protein, is a Novel Anti-Angiogenic Agent that Prevents Tumor Growth in an Orthotopic Model of Breast Cancer (AACR 2009)
Relevant Manuscripts:
ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. D. Mitchell, et al., Molecular Cancer Therapeutics. 9:379-88, 2010
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. S. Cunha, et al., Journal of Experimental Medicine. 207:85-100, 2010
BACK TO TOP
